Literature DB >> 12555674

Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.

Valérie Dutoit1, Philippe Guillaume, Jean-Charles Cerottini, Pedro Romero, Danila Valmori.   

Abstract

Soluble peptide/MHC-class-I (pMHC) multimers have recently emerged as unique reagents for the study of specific interactions between the pMHC complex and the TCR. Here, we assessed the relative binding efficiency of a panel of multimers incorporating single-alanine-substituted variants of the tumor-antigen-derived peptide MAGE-A10(254-262) to specific CTL clones displaying different functional avidity. For each individual clone, the efficiency of binding of multimers incorporating MAGE-A10 peptide variants was, in most cases, in good although not linear correlation with the avidity of recognition of the corresponding variant. In addition, we observed two types of discrepancies between efficiency of recognition and multimer binding. First, for some peptide variants, efficient multimer binding was detected in the absence of measurable effector functions. Some of these peptide variants displayed antagonist activity. Second, when comparing different clones we found clear discrepancies between the dose of peptide required to obtain half-maximal lysis in CTL assays and the binding efficiency of the corresponding multimers. These discrepancies, however, were resolved when the differential stability of the TCR/pMHC complexes was determined. For individual clones, decreased recognition correlated with increased TCR/pMHC off-rate. TCR/pMHC complexes formed by antagonist ligands displayed off-rates faster than those of TCR/pMHC complexes formed with weak agonists. In addition, when comparing different clones, the efficiency of multimer staining correlated better with relative multimer off-rates than with half-maximal lysis values. Altogether, the data presented here reconcile and extend our previous results on the impact of the kinetics of interaction of TCR with pMHC complexes on multimer binding and underline the crucial role of TCR/pMHC off-rates for the functional outcome of such interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555674     DOI: 10.1002/1521-4141(200211)32:11<3285::AID-IMMU3285>3.0.CO;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients.

Authors:  Yi Shao; Zhen-Yuan Sun; Shi-Wei Sun; Yi Zhao; Wan Yee Sin; Yan-Hua Yuan; Andrew J Simpson; Lloyd J Old; Xin-Ting Sang; Yi-Lei Mao; Yong Xie; Jie-Fu Huang; Hai-Tao Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-25       Impact factor: 4.553

Review 2.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

3.  Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

Authors:  Rachel H McMahan; Jennifer A McWilliams; Kimberly R Jordan; Steven W Dow; Darcy B Wilson; Jill E Slansky
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

4.  Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Authors:  Maha Ayyoub; Danijel Dojcinovic; Pascale Pignon; Isabelle Raimbaud; Julien Schmidt; Immanuel Luescher; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.

Authors:  Julien Schmidt; Philippe Guillaume; Melita Irving; Petra Baumgaertner; Daniel Speiser; Immanuel F Luescher
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

6.  Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects.

Authors:  Vaios Karanikas; Maria Zamanakou; Faye Soukou; Theodora Kerenidi; Ioannis Tsougos; Kiki Theodorou; Panagiotis Georgoulias; Konstantinos I Gourgoulianis; Anastasios E Germenis
Journal:  J Exp Clin Cancer Res       Date:  2010-06-04

Review 7.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

8.  T cell avidity and tumor recognition: implications and therapeutic strategies.

Authors:  Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  J Transl Med       Date:  2005-09-20       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.